Stockscreener 앱 받기
9.41
3.09%
-0.30
시간 외 거래:
9.42
0.010
+0.11%
전일 마감가:
$9.71
열려 있는:
$9.83
하루 거래량:
388.61K
Relative Volume:
2.43
시가총액:
$286.50M
수익:
$6.67M
순이익/손실:
$-47.55M
주가수익비율:
-6.2733
EPS:
-1.5
순현금흐름:
$-17.44M
1주 성능:
-7.24%
1개월 성능:
-15.30%
6개월 성능:
-18.88%
1년 성능:
+1,740%
1일 변동 폭
$9.265
$9.93
1주일 범위
$9.10
$11.21
52주 변동 폭
$9.10
$21.40
Crescent Biopharma Inc Stock (CBIO) Company Profile
명칭
Crescent Biopharma Inc
전화
617-430-5595
주소
300 FIFTH AVENUE, WALTHAM, CA
CBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
9.41 | 295.64M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.81 | 119.38B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.63 | 81.46B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
820.31 | 52.65B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.24 | 46.50B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.00 | 38.95B | 4.98B | 69.60M | 525.67M | 0.5198 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Piper Sandler | Overweight |
| 2026-01-21 | 개시 | Guggenheim | Buy |
| 2025-08-25 | 개시 | Jefferies | Buy |
| 2025-08-11 | 개시 | H.C. Wainwright | Buy |
| 2025-07-14 | 개시 | Wedbush | Outperform |
| 2025-06-25 | 개시 | Stifel | Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-11 | 개시 | Noble Capital Markets | Outperform |
| 2024-07-26 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-22 | 개시 | CapitalOne | Overweight |
| 2021-11-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-04-29 | 재개 | Stephens | Overweight |
| 2021-02-10 | 개시 | Piper Sandler | Overweight |
| 2020-05-21 | 개시 | Raymond James | Outperform |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-05 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-04-12 | 개시 | Piper Jaffray | Overweight |
| 2019-01-04 | 개시 | Oppenheimer | Outperform |
| 2018-12-18 | 개시 | H.C. Wainwright | Buy |
| 2018-02-12 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 재확인 | Chardan Capital Markets | Buy |
| 2017-12-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 개시 | Chardan Capital Markets | Buy |
| 2017-06-06 | 개시 | Ladenburg Thalmann | Buy |
| 2016-07-26 | 개시 | SunTrust | Buy |
| 2016-06-30 | 개시 | Rodman & Renshaw | Buy |
| 2015-03-17 | 재확인 | Stifel | Buy |
모두보기
Crescent Biopharma Inc 주식(CBIO)의 최신 뉴스
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Crescent Biopharma (CBIO) Price Target Increased by 10.69% to 29.92 - Nasdaq
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Crescent Biopharma Announces Grants of Inducement Awards - Chartmill
Crescent Biopharma (NASDAQ:CBIO) Upgraded to "Strong-Buy" at Piper Sandler - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Upgraded at Wall Street Zen - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Upgraded by Guggenheim to Strong-Buy Rating - MarketBeat
This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Guggenheim Initiates Crescent Biopharma(CBIO.US) With Buy Rating, Announces Target Price $35 - 富途资讯
Crescent Biopharma Advances CR-001 Cancer Trial Into First-in-Human Stage - TipRanks
The deal that sent Crescent Biopharma shares surging over 40% pre-market today - MSN
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Crescent and Kelun announce IND approvals for CR-001, CR-003 - BioWorld MedTech
Crescent Biopharma Secures IND Clearances For Two Novel Oncology Candidates - Nasdaq
Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA - BioSpace
FDA clears Crescent’s CR-001 IND for solid tumor treatment By Investing.com - Investing.com South Africa
FDA clears Crescent’s CR-001 IND for solid tumor treatment - Investing.com
Two experimental cancer drugs cleared to begin human trials in U.S., China - Stock Titan
Crescent Biopharma, Inc. (CBIO) - MSN
Crescent Biopharma (CBIO) Stock Analysis Report | Financials & Insights - Benzinga
Crescent Biopharma price target raised to $32 from $28 at Stifel - MSN
Crescent Biopharma (NASDAQ:CBIO) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Crescent Biopharma (NASDAQ:CBIO) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Stifel Initiates Coverage of Crescent Biopharma (CBIO) with Buy Recommendation - MSN
Can Crescent Biopharma Inc. (GKO0) stock sustain free cash flowWeekly Stock Recap & Trade Opportunity Analysis - Улправда
Is Crescent Biopharma Inc. (GKO0) stock dividend growth reliable2025 Growth vs Value & Safe Entry Trade Signal Reports - Улправда
Crescent Biopharma (CBIO) insider reports RSU and option awards - Stock Titan
Brokerages Set Crescent Biopharma, Inc. (NASDAQ:CBIO) Target Price at $26.40 - Defense World
Huge insider buying in MGM and Salesforce - MSN
Frazier Life Sciences Management L.P. Takes Position in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
CBIO Insider Trading - Quiver Quantitative
GlycoMimetics executives to depart amid merger plans - MSN
BVF Inc. IL Makes New Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
Braidwell LP Invests $4.22 Million in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma, Inc. (CBIO) Stock News & Articles - 24/7 Wall St.
Huge Insider Buying in MGM and Salesforce - 24/7 Wall St.
Crescent Biopharma (NASDAQ:CBIO) Director Fairmount Funds Management Llc Purchases 1,360,000 Shares of Stock - Defense World
Crescent, Kelun in two-way deal, including PD-1/VEGF bispecific - BioWorld MedTech
Fairmount Funds Management Llc Purchases 1,360,000 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock - MarketBeat
Shareholder Fairmount Funds Management LLC Buys 1,360,000 ($18.2M) Of Crescent Biopharma Inc [CBIO] - TradingView — Track All Markets
Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership - Indian Pharma Post
Sichuan Kelun-Biotech partners with Crescent Biopharma for oncology advancements - MSN
Affinity Asset Advisors LLC Makes New $4.52 Million Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
China's Kelun-Biotech licenses cancer treatment to Crescent Biopharma - Reuters
Crescent Biopharma (NASDAQ:CBIO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Lowered to “Sell” Rating by Wall Street Zen - Defense World
Crescent Biopharma partners with Kelun-Biotech in oncology - BioWorld MedTech
Crescent and Kelun-Biotech swap cancer asset rights in double deal - Yahoo Finance
Crescent Biopharma Inc (CBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.96%
2.92%
자본화:
|
볼륨(24시간):